Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  JACC. Heart failure

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jchf.2013.11.004PMID 24720917PMCID PMC3984539
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.

  2013influential reference
• Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome

  2013cited by this paper
• SENSITIVITY OF SUBCUTANEOUS FAT ASPIRATE BIOPSY FOR DETECTION OF SYSTEMIC AMYLOIDOSIS IN CARDIAC BIOPSY-PROVEN TRANSTHYRETIN CARDIOMYOPATHY

  2013cited by this paper
• Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy

  2012cited by this paper
• Cardiac transthyretin amyloidosis

  2012cited by this paper
• Senile systemic amyloidosis: are regional differences real or do they reflect different diagnostic suspicion and use of techniques?

  2012cited by this paper
• On typing amyloidosis using immunohistochemistry. Detailled illustrations, review and a note on mass spectrometry.

  2012cited by this paper
• Why are some amyloidoses systemic? Does hepatic “chaperoning at a distance” prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis?

  2012cited by this paper
• Tafamidis

  2012cited by this paper
• Molecular and Cellular Basis for Diastolic Dysfunction

  2012cited by this paper
• Redox Signaling in Cardiac Physiology and Pathology

  2012cited by this paper
• Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis

  2011cited by this paper
• Diastolic and Systolic Heart Failure Are Distinct Phenotypes Within the Heart Failure Spectrum

  2011cited by this paper
• Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

  2011cited by this paper
• Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity

  2011cited by this paper
• A status report on RNAi therapeutics

  2010cited by this paper
• Biological and chemical approaches to diseases of proteostasis deficiency.

  2009cited by this paper
• Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.

  2009influential reference
• Anemia and heart failure: a community study.

  2008cited by this paper
• Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2‐macroglobulin and tau: A population‐based autopsy study

  2008cited by this paper
• Trends in prevalence and outcome of heart failure with preserved ejection fraction.

  2006cited by this paper
• Secular trends in renal dysfunction and outcomes in hospitalized heart failure patients.

  2006cited by this paper
• Epidemiology of diastolic heart failure.

  2005cited by this paper
• Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis.

  2005cited by this paper
• Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis.

  2005cited by this paper
• Use of N-terminal pro-B-type natriuretic peptide to detect myocardial ischemia.

  2005cited by this paper
• Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement.

  2005cited by this paper
• Referral to autopsy: effect of antemortem cardiovascular disease: a population-based study in Olmsted County, Minnesota.

  2001influential reference
• Amyloid and Nonfibrillar Deposits in Mice Transgenic for Wild-Type Human Transthyretin: A Possible Model for Senile Systemic Amyloidosis

  2001cited by this paper
• Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates.

  2001cited by this paper
• Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.

  1997cited by this paper
• The premortem recognition of systemic senile amyloidosis with cardiac involvement.

  1996cited by this paper
• Premortem recognition of systemic senile amyloidosis with cardiac involvement

  1996cited by this paper
• Ethnic distribution of amyloidosis: an autopsy study.

  1989cited by this paper
• Age-related changes in normal human hearts during the first 10 decades of life. Part II (Maturity): A quantitative anatomic study of 765 specimens from subjects 20 to 99 years old.

  1988influential reference
• Pathology of the senescent heart: anatomic observations on 237 autopsy studies of patients 90 to 105 years old.

  1988cited by this paper
• Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement.

  1988cited by this paper
• [Senile cardiac amyloidosis].

  1988cited by this paper
• Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation.

  1983cited by this paper
• The clinical significance of senile cardiac amyloidosis: a prospective clinico-pathological study.

  1977cited by this paper
• Amyloid in the Aged Heart: Frequency and Clinical Significance

  1975cited by this paper
• Senile cardiac amyloidosis.

  1960cited by this paper

• Global Burden of Cardiac Amyloidosis in Heart Failure: A Systematic Review and Meta-Analysis

  2026cites this paper
• Proteomics Profiling Reveals Circulating Biomarkers and Dysregulated Pathways in Transthyretin Amyloid Cardiomyopathy.

  2026cites this paper
• Ocular Manifestations of Transthyretin Amyloidosis and Their Diagnostic Value in Cardiology: A Comprehensive Review.

  2026cites this paper
• Trends and disparities in amyloidosis and cardiovascular disease mortality: a population-based retrospective study in the United States (1999–2020)

  2026cites this paper
• A Pragmatic Framework for Shared Decision Making in Older Adults: Cardiac Amyloidosis as a Prototype.

  2026cites this paper
• Hidden overlap between heart failure with preserved ejection fraction and transthyretin amyloid cardiomyopathy: Why it matters and how to avoid missing it.

  2026cites this paper
• Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

  2026cites this paper
• Bridging the Gap in AL and ATTR Cardiac Amyloidosis: Integrating Histopathology, Biomarkers, and Multimodal Imaging for Subtype-Specific Diagnosis

  2026cites this paper
• [Effect of sodium-glucose cotransporter type 2 inhibitors on the course of heart failure in patients with amyloid cardiomyopathy: Results of a pilot single-center randomized trial].

  2026cites this paper
• Prognostic parameters and detection of cardiac amyloidosis with hybrid 18F-Florbetaben-PET/MRI: an exploratory observational study.

  2026cites this paper
• Single-cell transcriptomic profiling reveals cell type heterogeneity between HFpEF and HFrEF

  2025cites this paper
• Role of [99mTc]Tc-DPD gated-SPECT-CT in the assessment of myocardial uptake patterns in transthyretin amyloidosis (TTR-CA).

  2025cites this paper
• Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment

  2025cites this paper
• A Case Report and Literature Review of Cardiac Amyloidosis: The Great Pretender Masquerading As Acute Coronary Syndrome

  2025cites this paper
• Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis: An Update From the American Society of Echocardiography.

  2025cites this paper
• Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications

  2025cites this paper
• Value of Artificial Intelligence for Enhancing Suspicion of Cardiac Amyloidosis Using Electrocardiography and Echocardiography: A Narrative Review

  2025cites this paper
• Transthyretin Amyloid Cardiomyopathy Treatment: An Updated Review

  2025cites this paper
• Advances in Cardiovascular Pharmacotherapy. V. Molecular Targets in Transthyretin Amyloid Cardiomyopathy.

  2025cites this paper
• Echocardiographic Phenotypic Differences between Light Chain and Transthyretin Cardiac Amyloid and Relation to Outcome.

  2025cites this paper
• Distinguishing between mortality rates for heart failure with preserved versus reduced ejection fraction - Authors' reply.

  2025cites this paper
• Present and future of endomyocardial biopsy in cardiac amyloidosis

  2025cites this paper
• Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool

  2025cites this paper
• Cardiac Amyloidosis in Older Adults With a Focus on Frailty

  2025cites this paper
• Transthyretin Amyloid Cardiomyopathy - Early Diagnosis is the Key for Better Outcomes

  2025cites this paper
• Wild-type transthyretin cardiac amyloidosis in a 56-year-old patient: A case report

  2025cites this paper
• Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance.

  2025cites this paper
• [1. The Role of Imaging Modalities in Heart Failure].

  2025cites this paper
• The Weight of Comorbidities in the Specific Treatment of ATTR-Related Amyloid Cardiomyopathy

  2025cites this paper
• Cardiac amyloidosis in a Swiss autopsy cohort - distribution and clinical relevance.

  2025cites this paper
• Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift

  2025cites this paper
• Development and validation of a radiomics model for detecting cardiac amyloidosis at coronary CT angiography.

  2025cites this paper
• Myocardial T1 Mapping, Left Ventricular Parameters, and Cardiac Biomarkers in Wild-Type Transthyretin Amyloid Cardiomyopathy Before and After Tafamidis Treatment

  2025cites this paper
• Multimodality Imaging in Cardiac Amyloidosis

  2025cites this paper
• Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study

  2025cites this paper
• Delayed Diagnosis of Transthyretin Amyloid Cardiomyopathy in the Modern Era: Seeing the Forest through the Trees.

  2025cites this paper
• Comparative Outcomes and Cardiac Imaging Features in Light Chain Versus Transthyretin Cardiac Amyloidosis: A Multi-Center Retrospective Cohort Study.

  2025cites this paper
• Cardiac Amyloidosis: A Narrative Review of Diagnostic Advances and Emerging Therapies

  2025cites this paper
• Standard Therapy in Cardiac Amyloidosis: What is Known, What is "Gray".

  2024cites this paper
• Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years

  2024cites this paper
• Transthyretin amyloid cardiomyopathy in patients with unexplained increased left ventricular wall thickness

  2024cites this paper
• Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment

  2024cites this paper
• Chest pain in a patient with transthyretin cardiac amyloidosis: A case report

  2024cites this paper
• Prognostic Value of Standard Heart Failure Medication in Patients with Cardiac Transthyretin Amyloidosis

  2024cites this paper
• Clinical suspicion, diagnosis and management of cardiac amyloidosis: update document and executive summary.

  2024cites this paper
• Cardiac Amyloidosis Due to Transthyretin Protein: A Review.

  2024cites this paper
• Detection of cardiac amyloidosis on routine bone scintigraphy: an important gatekeeper role for the nuclear medicine physician

  2024cites this paper
• Outcomes of Octogenarian Patients Treated with Tafamidis for Transthyretin Amyloid Cardiomyopathy.

  2024cites this paper
• Два брати – дві хвороби (гіпертрофійна кардіоміопатія і амілоїдоз серця): причини різні чи одна й та ж (огляд літератури, опис клінічних випадків)

  2024cites this paper
• Temporal outcomes of patients diagnosed with transthyretin cardiac amyloidosis.

  2024cites this paper
• 2024 Australia-New Zealand Expert Consensus Statement on Cardiac Amyloidosis.

  2024cites this paper
• Complexities of Coexisting Cardiac Amyloidosis and Coronary Artery Disease: A Contemporary Review of Diagnostic and Treatment Approaches.

  2024cites this paper
• Sospecha clínica, diagnóstico y seguimiento de la amiloidosis cardíaca: documento de actualización y resumen ejecutivo

  2024cites this paper
• A Case Report of Korean Medicine Treatment for Cardiac Amyloidosis

  2024cites this paper
• Wild-Type Transthyretin Amyloidosis: A Prevalent and Underdiagnosed Cause of Heart Failure With Preserved Ejection Fraction

  2024cites this paper
• Detection of cardiac amyloidosis using machine learning on routine echocardiographic measurements

  2024cites this paper
• Papel del [99mTc]Tc-DPD gated-SPECT-TC en la evaluación de los patrones de captación miocárdica de la amiloidosis por transtiretina (AC-TTR)

  2024cites this paper
• Evolving knowledge of "red flag" clinical features associated with TTR p.(Val142Ile) in a diverse electronic health record-linked biobank.

  2024cites this paper
• Molecular mechanisms and emerging therapies in wild-type transthyretin amyloid cardiomyopathy

  2024cites this paper
• Diastolic Dysfunction Unveiling Cardiac Light-Chain Amyloidosis: A Case Report

  2024cites this paper
• Amyloidosis in Childhood: A Review of Clinical Features and Comparison with Adult Forms

  2024cites this paper
• Reproducibility of myocardial extracellular volume quantification using dual-energy computed tomography in patients with cardiac amyloidosis.

  2024cites this paper
• RV-PA uncoupling is associated with increased mortality in transthyretin amyloid cardiomyopathy treated with tafamidis.

  2024cites this paper
• Assessing left atrial dysfunction in cardiac amyloidosis using LA–LV strain slope

  2024cites this paper
• Analysis and insights of cardiac amyloidosis: novel perception of rare diseases in cardiology.

  2024cites this paper
• First report of the clinical characteristics and outcomes of cardiac amyloidosis in Saudi Arabia

  2024cites this paper
• The Impact of Active Ascertainment on Sex-Specific Differences in the Prevalence and Phenotype of Transthyretin Cardiac Amyloidosis: The SCAN-MP Study.

  2024cites this paper
• Prevalence, clinical significance and prognosis value of liver stiffness measurement anomalies in transthyretin cardiac amyloidosis.

  2024cites this paper
• Syncope and Rhythm Disturbances as Common Clinical Manifestations in Amyloidosis

  2024cites this paper
• Epidemiological Changes in Transthyretin Cardiac Amyloidosis: Evidence from In Vivo Data and Autoptic Series

  2024cites this paper
• Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin Amyloidosis

  2024cites this paper
• Nuclear imaging techniques for cardiac amyloidosis

  2024cites this paper
• Is It Time for Population-Based Screening for Transthyretin Cardiac Amyloidosis?

  2024cites this paper
• 18F-Florbetaben PET/CT for the Diagnosis and Subtyping of Cardiac Amyloidosis: A Case Series and Review of the Literature.

  2024cites this paper
• Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study.

  2024cites this paper
• Prospective Multicenter Screening With High-Sensitivity Cardiac Troponin T for Wild-Type Transthyretin Cardiac Amyloidosis in Outpatient and Community-Based Settings.

  2024cites this paper
• Pathophysiological insights into HFpEF from studies of human cardiac tissue

  2024cites this paper
• Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy.

  2024cites this paper
• Resistance training improves cardiac function in older women: a randomized controlled trial

  2024cites this paper
• Global epidemiology of heart failure

  2024cites this paper
• Transthyretin Cardiac Amyloidosis in Australia and New Zealand-A Multi-Site Snapshot for 2022.

  2024cites this paper
• Detecting transthyretin amyloid cardiomyopathy (ATTR-CM) using machine learning: an evaluation of the performance of an algorithm in a UK setting

  2023cites this paper
• Developing, optimizing, and evaluating patient infographics for diagnosing cardiac amyloidosis

  2023cites this paper
• Fibroblasts and Immune Cells: At The Cross-Road of Organ Inflammation and Fibrosis.

  2023cites this paper
• Sex differences in transthyretin cardiac amyloidosis

  2023cites this paper
• Myocardial extracellular volume quantification in cardiac amyloidosis: a comparative study between cardiac computed tomography and magnetic resonance imaging

  2023cites this paper
• Uneven burden of cardiac amyloidosis in people of African descent — global imbalance in resources and access

  2023cites this paper
• Healthcare and economic burden of heart failure with amyloidosis: An insight from National Readmission Database.

  2023cites this paper
• Current and Evolving Multimodality Cardiac Imaging in Managing Transthyretin Amyloid Cardiomyopathy.

  2023cites this paper
• Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France.

  2023cites this paper
• Unfolding the Intricate Details of an Unspoken Threat - Transthyretin Amyloid Cardiomyopathy

  2023cites this paper
• Prognostic Impact of the Increase in Cardiac Troponin Levels during Tafamidis Therapy in Patients with Transthyretin Cardiac Amyloidosis

  2023cites this paper
• 2023 Expert Consensus of the Taiwan Society of Cardiology on the Diagnosis and Treatment of Cardiac Amyloidosis.

  2023cites this paper
• World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

  2023cites this paper
• Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?

  2023cites this paper
• A simple ATTR‐CM score to identify transthyretin amyloid cardiomyopathy burden in HFpEF patients

  2023cites this paper
• Transthyretin Amyloid Cardiomyopathy Among Patients Hospitalized for Heart Failure and Performance of an Adapted Wild-Type ATTR-CM Machine Learning Model: Findings from GWTG-HF.

  2023cites this paper
• Quantitative ATTR-cardiac amyloidosis SPECT/CT imaging: The time is now!

  2023cites this paper
• The mTOR signaling pathway in cardiac aging

  2023cites this paper
• Becker Digital

  2023cites this paper